The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs
Value in Health · 2025
DOI: 10.1016/j.jval.2025.08.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2025. Verfasst von Robert J Nordyke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beta6 Consulting Group, Los Angeles, CA, USA. Electronic address: bnordyke@gmail.com. Hauptthemen laut MEDLINE: Drug Development, Negotiating, Drug Costs, Motivation. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Pharmaceutical Council.
Abstract (Originalsprache)
OBJECTIVES: We explore the impact of the Drug Price Negotiation Program (DPNP) on investment incentives for drug research and development (R&D). METHODS: We modeled 5 hypothetical scenarios of future drugs selected for the DPNP. Scenarios were defined by disease area, post-approval development strategy, and potential responses to the DPNP, such as delaying, resequencing, or canceling additional indications. We estimated risk-adjusted net present values and internal rates of return at 3 points during development of initial indications: beginning of phase 1, phase 2 (accelerated approval) or 3 (others), and Food and Drug Administration approval. Small molecules and biologics were modeled. RESULTS: The DPNP had a substantial impact on estimated investment returns across disease areas and post-approval development strategies for the modeled drugs that were assumed to be selected for the program. At the start of phase 1 for the initial indication, DPNP reduced the modeled discounted value of projects, and the estimated net present value reductions ranged from 22% to 95% for small molecules and 14% to 45% for biologics. Estimated internal rates of return were also reduced, by 5% to 14% for small molecules and 3% to 7% for biologics. No modeled response restored investment incentives to pre-DPNP levels; however, some modeled responses improved estimated returns relative to post-DPNP. CONCLUSIONS: Examples illustrated how the DPNP may negatively affect R&D investment incentives for small molecules and biologics that were likely to be selected. Although short-term observed effects may be limited, over the longer term, DPNP-induced reductions in investment incentives may redirect funding away from programs with the largest expected impacts, potentially leading to far-reaching implications for drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beta6 Consulting Group, Los Angeles, CA, USA. Electronic address: bnordyke@gmail.com.
- National Pharmaceutical Council, Washington, DC, USA.
- Analysis Group, Boston, MA, USA.
- Genia Long Consulting, Boston, MA, USA.
Förderung
- National Pharmaceutical Council
Zitieren
APA
Nordyke, R. J., Patterson, J. A., Motyka, J., March, B., Kirson, N. Y., & Long, G. (2025). The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs. Value in Health. https://doi.org/10.1016/j.jval.2025.08.011
Vancouver
Nordyke RJ, Patterson JA, Motyka J, March B, Kirson NY, Long G. The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs. Value in Health. 2025. doi:10.1016/j.jval.2025.08.011
BibTeX
@article{Nordyke2025,
author = {Nordyke, Robert J and Patterson, Julie A and Motyka, James and March, Benjamin and Kirson, Noam Y and Long, Genia},
title = {The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs},
journal = {Value in Health},
year = {2025},
doi = {10.1016/j.jval.2025.08.011}
}
EUVIMED